



The relative strengths and weaknesses of Viridian Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 420% points. The greatest weakness of Viridian Therapeutics Inc DE is the variable Other Revenues, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 368%, being 303% points above the market average of 65%.

Input Variable	Value in 1000 USD
Assets, Current	486,478
Assets, Non-Current	2,274
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	94,999
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	26,635
Long Term Liabilities	989
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	728
Other Expenses	159,765
Other Liabilities	20,778
Other Net Income	16,716
Other Revenues	314
Property Plant and Equipment	1,672
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	490,424
Liabilities	48,402
Expenses	254,764
Revenues	314
Stockholders Equity	442,022
Net Income	-237,734
Comprehensive Net Income	-237,006
Economic Capital Ratio	368%